母鼠糖尿病模型中胎儿生长的双相β细胞反应及生酮饮食的重塑作用
该研究在母鼠孕前糖尿病模型中按母体血糖分层(非糖尿病<9.6 mmol/l、轻度9.6-16.7 mmol/l、重度>16.7 mmol/l),发现轻度糖尿病经β细胞增生和高胰岛素血症导致巨大儿,重度糖尿病则因β细胞质量减少和功能受损导致IUGR;生酮饮食可预防轻度组的巨大儿但无法挽救重度组的IUGR。
要点
- 母体高血糖程度决定胎儿β细胞双相反应:轻度→巨大儿,重度→IUGR。
- 生酮饮食通过抑制β细胞增殖和早熟减少胰岛素分泌,预防轻度糖尿病巨大儿。
- 生酮饮食不能逆转重度糖尿病的IUGR,且存在不依赖胰岛素的生长限制效应。
核心结论
- 小鼠妊娠糖尿病模型中,胎儿生长由母体血糖环境驱动的双相β细胞反应决定,mTORC1通路参与分子调控。
- 生酮饮食可预防糖尿病相关巨大儿,但不能逆转IUGR。
研究设计与样本
- 使用Insulin-rtTA;TET-DTA小鼠模型诱导孕前糖尿病,按母体血糖分为非糖尿病(<9.6 mmol/l)、轻度糖尿病(9.6-16.7 mmol/l)和重度糖尿病(>16.7 mmol/l)三组。
- 各组维持正常饮食或生酮饮食,评估胎儿生长、血浆C肽、离体胰岛功能、血浆代谢物及胎儿胰腺免疫组化(β细胞面积、增殖、成熟、mTORC1活性)。
主要发现
- 轻度母体糖尿病诱导胎儿巨大儿,伴β细胞增生、高胰岛素血症和β细胞功能早熟(葡萄糖刺激胰岛素分泌和MafA表达上调),mTORC1通路强烈激活。
- 重度糖尿病导致IUGR,伴β细胞质量减少和严重功能损伤。
- 生酮饮食使轻度糖尿病组胎儿生长正常化,通过阻止β细胞增殖和早熟降低胰岛素分泌。
- 生酮饮食未能挽救重度糖尿病组的IUGR,尽管部分恢复β细胞功能。
- 生酮饮食解耦了胎儿胰岛素与体重的正相关,揭示不依赖胰岛素的生长限制效应。
关键数值与推荐
- 母体血糖分层阈值:非糖尿病<9.6 mmol/l,轻度糖尿病9.6-16.7 mmol/l,重度糖尿病>16.7 mmol/l。
临床怎么用
- 提示临床对妊娠糖尿病需关注母体血糖严重程度对胎儿生长的双相影响,轻度者警惕巨大儿,重度者警惕IUGR。
- 生酮饮食在妊娠糖尿病中的应用需谨慎:可能预防巨大儿但无法改善IUGR,且存在不依赖胰岛素的生长限制效应。
局限性
- 本研究为小鼠模型,结论外推至人类需进一步验证。
- 生酮饮食在妊娠糖尿病中的作用需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Maternal diabetes confers two opposing risks to fetal growth, resulting in macrosomia in mild cases and intrauterine growth restriction (IUGR) in severe cases. The mechanisms governing these divergent responses are poorly understood, given the intimate regulation of insulin by glucose and insulin's fetal growth-promoting effects. We hypothesised that the degree of maternal hyperglycaemia dictates a bimodal pattern of fetal insulin secretion that determines fetal growth, and that use of a ketogenic diet (KD) as a nutritional intervention could modify this outcome. METHODS: We used the Insulin-rtTA;TET-DTA mouse model to induce preconception diabetes. Dams were stratified based on maternal blood glucose, namely non-diabetes (glucose <9.6 mmol/l), mild diabetes (glucose range 9.6-16.7 mmol/l) or severe diabetes (glucose >16.7 mmol/l), and maintained on either a normal diet or a KD. We assessed fetal growth and plasma C-peptide, performed islet functional assays ex vivo, and characterised changes in plasma metabolites. Fetal pancreases were analysed by immunohistochemistry for beta cell area, proliferation, maturation and mechanistic target of rapamycin complex 1 (mTORC1) activity. RESULTS: Mild maternal diabetes induced fetal macrosomia, driven by beta cell hyperplasia, hyperinsulinaemia and premature beta cell functional maturation, as reflected by glucose-stimulated insulin secretion and upregulated MafA expression. This was associated with strong activation of the mTORC1 pathway. In contrast, severe diabetes caused IUGR associated with reduced beta cell mass and profound functional impairment. The KD had divergent effects: it normalised fetal growth in the mild diabetes group by preventing beta cell proliferation and premature maturation, thereby reducing insulin secretion, but failed to rescue IUGR in the severe diabetes group, despite partially restoring beta cell function. Notably, the KD uncoupled the positive correlation between fetal insulin and body weight, revealing a primary, insulin-independent, growth-restrictive effect. CONCLUSIONS/INTERPRETATION: Fetal growth in a mouse model of diabetes in pregnancy is governed by a bimodal beta cell response to the maternal glycaemic environment, orchestrated at the molecular level by the mTORC1 pathway. A KD can prevent diabetes-derived macrosomia by reducing beta cell stimulation and through insulin-independent mechanisms, but cannot reverse IUGR, warranting further studies of its role in diabetes during pregnancy.
引用
- Cohenshtam O, Zung A, Yu A, et al. Fetal growth is driven by a bimodal fetal beta cell response and reshaped by a ketogenic diet in a mouse model of maternal diabetes. Diabetologia. 2026. PMID: 42265456. doi:10.1007/s00125-026-06771-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。